These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 23726889)

  • 41. Therapeutic modulators of STAT signalling for human diseases.
    Miklossy G; Hilliard TS; Turkson J
    Nat Rev Drug Discov; 2013 Aug; 12(8):611-29. PubMed ID: 23903221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
    Talele SS; Xu K; Pariser AR; Braun MM; Farag-El-Massah S; Phillips MI; Thompson BH; Coté TR
    Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development.
    Shah ED; Fisch BM; Arceci RJ; Buckley JD; Reaman GH; Sorensen PH; Triche TJ; Reynolds CP
    Cancer Chemother Pharmacol; 2014 May; 73(5):1089-93. PubMed ID: 24663501
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How many drug targets are there?
    Overington JP; Al-Lazikani B; Hopkins AL
    Nat Rev Drug Discov; 2006 Dec; 5(12):993-6. PubMed ID: 17139284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging peptide therapeutics for inflammatory autoimmune diseases.
    Briand JP; Muller S
    Curr Pharm Des; 2010; 16(9):1136-42. PubMed ID: 20030611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A forensic analysis of drug targets from 2000 through 2012.
    Munos B
    Clin Pharmacol Ther; 2013 Sep; 94(3):407-11. PubMed ID: 23756372
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.
    Góngora-Benítez M; Tulla-Puche J; Albericio F
    Future Med Chem; 2013 Mar; 5(3):291-300. PubMed ID: 23464519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peptide therapeutics for CNS indications.
    McGonigle P
    Biochem Pharmacol; 2012 Mar; 83(5):559-66. PubMed ID: 22051078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Biomarkers: "Found in translation"].
    Lockhart BP; Walther B
    Med Sci (Paris); 2009 Apr; 25(4):423-30. PubMed ID: 19409197
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development and Regulatory Challenges for Peptide Therapeutics.
    Zane D; Feldman PL; Sawyer T; Sobol Z; Hawes J
    Int J Toxicol; 2021; 40(2):108-124. PubMed ID: 33327828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current strategies for the development of peptide-based anti-cancer therapeutics.
    Borghouts C; Kunz C; Groner B
    J Pept Sci; 2005 Nov; 11(11):713-26. PubMed ID: 16138387
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Challenges and prospects for drug development of molecular targeting agents in Japan].
    Iwasaki M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():695-702. PubMed ID: 23513923
    [No Abstract]   [Full Text] [Related]  

  • 54. Progress towards novel adenosine receptor therapeutics gleaned from the recent patent literature.
    Press NJ; Fozard JR
    Expert Opin Ther Pat; 2010 Aug; 20(8):987-1005. PubMed ID: 20649373
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of protein therapeutics by mass spectrometry: recent developments and future directions.
    Chen G; Warrack BM; Goodenough AK; Wei H; Wang-Iverson DB; Tymiak AA
    Drug Discov Today; 2011 Jan; 16(1-2):58-64. PubMed ID: 21093608
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
    Roberts SA; Allen JD; Sigal EV
    Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [International comparison and regulatory issues of the molecular targeted therapy development].
    Iwasaku M; Kawakami K
    Nihon Rinsho; 2015 Aug; 73(8):1403-8. PubMed ID: 26281697
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
    Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
    Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
    [No Abstract]   [Full Text] [Related]  

  • 60. Folate-targeted drug strategies for the treatment of cancer.
    Leamon CP
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1277-86. PubMed ID: 19037834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.